Daniel Devine Co buys $2,494,538 stake in Pfizer (PFE)

Pfizer (PFE) : Daniel Devine Co scooped up 26,427 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 13, 2016. The investment management firm now holds a total of 76,755 shares of Pfizer which is valued at $2,494,538.Pfizer makes up approximately 1.60% of Daniel Devine Co’s portfolio.

Pfizer opened for trading at $32.3 and hit $32.86 on the upside on Monday, eventually ending the session at $32.61, with a gain of 0.34% or 0.11 points. The heightened volatility saw the trading volume jump to 3,69,99,336 shares. Company has a market cap of $201,665 M.

Other Hedge Funds, Including , Somerset Trust Co reduced its stake in PFE by selling 364 shares or 0.43% in the most recent quarter. The Hedge Fund company now holds 85,089 shares of PFE which is valued at $2,765,393. Pfizer makes up approx 1.81% of Somerset Trust Co’s portfolio.Lynch Associatesin reduced its stake in PFE by selling 1,372 shares or 0.89% in the most recent quarter. The Hedge Fund company now holds 152,598 shares of PFE which is valued at $4,959,435. Pfizer makes up approx 2.33% of Lynch Associatesin’s portfolio.Foundation Resource Management Inc reduced its stake in PFE by selling 17,425 shares or 1.09% in the most recent quarter. The Hedge Fund company now holds 1,574,276 shares of PFE which is valued at $50,203,662. Pfizer makes up approx 10.12% of Foundation Resource Management Inc’s portfolio.Stock Yards Bank Trust Co reduced its stake in PFE by selling 10,880 shares or 6.42% in the most recent quarter. The Hedge Fund company now holds 158,625 shares of PFE which is valued at $5,058,551. Pfizer makes up approx 0.73% of Stock Yards Bank Trust Co’s portfolio.Hollencrest Securities boosted its stake in PFE in the latest quarter, The investment management firm added 750 additional shares and now holds a total of 198,798 shares of Pfizer which is valued at $6,339,668. Pfizer makes up approx 1.11% of Hollencrest Securities’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.